Axitinib: a review in advanced renal cell carcinoma

Related Experiment Video

Updated: Mar 31, 2026

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K

Gillian M Keating1

  • 1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.

Drugs
|October 22, 2015
PubMed

Insights

Axitinib (Inlyta) significantly improved progression-free survival in patients with advanced renal cell carcinoma (RCC) previously treated with other therapies. It offers a manageable safety profile, making it a valuable second-line treatment option.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Advanced renal cell carcinoma (RCC) remains a significant clinical challenge.
  • Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors are a key therapeutic class.
  • Previous treatments for advanced RCC have limitations.

Purpose of the Study:

  • To review the clinical efficacy and tolerability of axitinib (Inlyta).
  • To summarize the pharmacological properties of axitinib.
  • To evaluate axitinib as a second-line treatment for advanced RCC.

Main Methods:

  • Review of the pivotal Phase III AXIS trial data.
  • Comparison of axitinib versus sorafenib in previously treated advanced RCC patients.
  • Assessment of progression-free survival (PFS) and objective response rate (ORR).

Main Results:

  • Axitinib significantly prolonged median PFS compared to sorafenib (primary endpoint).
  • Higher ORR was observed with axitinib versus sorafenib.
  • No significant difference in median overall survival between groups.
  • Manageable tolerability profile with common adverse events including diarrhea and hypertension.

Conclusions:

  • Axitinib demonstrates significant efficacy in second-line treatment of advanced RCC.
  • Axitinib offers a favorable benefit-risk profile for previously treated patients.
  • Axitinib represents an important therapeutic option for advanced RCC.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K
Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K